Clinical Utility of the XF-1600 Flow Cytometer for MRD Assessment in Multiple Myeloma

The XF-1600 flow cytometer stands as a transformative force in clinical laboratory analysis, providing researchers and clinicians with a robust, high-performance platform for advanced cell analysis. Its enhanced sensitivity, multiplexing capabilities, and user-friendly interface have revolutionized the field of flow cytometry, paving the way for more accurate diagnoses, personalized treatment approaches, and improved patient outcomes. As the field of medicine continues to evolve, the XF-1600 is poised to play an even more pivotal role in shaping the future of clinical diagnostics and patient care. Here we show evidence of the clinical utility of the XF-1600 as a valuable tool for MRD assessment in multiple myeloma patients. We present a standardized and a reproducible panel for MRD detection in XF-1600 and compare the MRD assessment in n = 31 bone marrow specimens from multiple myeloma patients in XF-1600TM versus DxFlex and Navios EX Flow Cytometers (Beckman Coulter). MRD results obtained in XF-1600 strongly correlate with those ones obtained in DxFlex and Navios EX Flow Cytometers, providing compelling evidence that the XF-1600 flow cytometer is a reliable and accurate instrument for measuring MRD in MM.